Nova Eye Medical Limited (EYE) Q3 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning everyone and once again thanks for joining us. We'll cover a couple of things today with an over-eye. Obviously the March quarter result. We'll cover the record April sales release that we've put out to the ASX and our guidance today as well. And also we'll give you an update on how the US business is scaling up at this present time. Quick reminder, this session may include some forward-looking statements, so please refer to the ASX release and the investor presentation for full details. As always, if you'd like to ask a question, please use the Q&A function in Zoom and we will try and get to as many as we can. I have received a number of questions ahead of the meeting, so thank you to those that have sent those through. But with no further ado, hands straight over to Tom. Thanks, Mark. Thank you very much, everybody, for tuning in today. I'm always very pleased with the number of people that take the time to listen to our stories. I think we've got a good story again for the quarter to 31 March 2026. Just a reminder, it's about pressure. Glaucoma is about pressure. And us intervening in the disease to open up blockages and reduce that pressure. Next slide. The messages from today... We address, Nova iProducts address a genuine and growing clinical need. So we're not trying to make people do something they haven't done before. The disease is real. The customer base is real. There is competition, but that just means that we have an offering that participates very well. Our revenues are now up near $23 million annually and growing 25% plus year on year. and they reflect that real market demand. This quarter showed that we can grow revenue while also improving profitability. I've been saying that too for a while. We were just $75,000 short, just 1% of reven...